Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis

Hiroe Ogawa, Hideto Kameda, Hayato Nagasawa, Naoya Sekiguchi, Hirofumi Takei, Kensei Tsuzaka, Koichi Amano, Tsutomu Takeuchi

研究成果: Article

29 引用 (Scopus)

抜粋

We evaluated the efficacy and safety of low-dose cyclosporine A (CsA) in patients with refractory lupus nephritis. Nine patients with systemic lupus erythematosus who had lupus nephritis resistant to previous treatment with glucocorticoids and immunosuppressants other than CsA were enrolled in a prospective, open-label study. All patients initially received 2.5 mg/kg per day of CsA; the dosage was adjusted to reach a blood trough level of 80-150ng/ml. The urinary protein concentration decreased significantly 2 weeks after the initiation of treatment. After 30 weeks of CsA treatment, the mean urinary protein concentration was more than 50% lower than the baseline value, and urinary casts had decreased significantly. There were no significant changes in the levels of serum creatinine, serum anti-double-stranded DNA antibodies, or CH50 during any part of the study. The dose of glucocorticoids was significantly tapered by approximately 50%, without any disease flare. Hypertension developed in one patient, but was controlled with antihypertensive agents. Our results suggest that low-dose CsA therapy is an effective and less toxic alternative to conventional cyclophosphamide therapy for the management of refractory lupus nephritis.

元の言語English
ページ(範囲)92-97
ページ数6
ジャーナルModern rheumatology
17
発行部数2
DOI
出版物ステータスPublished - 2007 4 1

    フィンガープリント

ASJC Scopus subject areas

  • Rheumatology

これを引用

Ogawa, H., Kameda, H., Nagasawa, H., Sekiguchi, N., Takei, H., Tsuzaka, K., Amano, K., & Takeuchi, T. (2007). Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis. Modern rheumatology, 17(2), 92-97. https://doi.org/10.1007/s10165-006-0545-8